AbbVie’s future growth hinges on its leading immunology portfolio, particularly Skyrizi and Rinvoq. Management has raised combined sales guidance for these two therapies from $27 billion to $31 billion by 2027 after they exceeded expectations across indications such as plaque psoriasis, rheumatoid arthritis, ulcerative colitis and eczema. With patent protection extending well beyond 2030, these products are poised to drive double-digit revenue expansion over the next five years and fill the gap left by Humira’s patent expiration.

In 2024 AbbVie invested nearly $11 billion in research and development, supporting a pipeline of roughly 90 molecules across oncology, neuroscience and immunology. Third-quarter revenue rose 9% year-over-year, with immunology and neuroscience segments up 12% and 20% respectively. Gross margins near 70% and a forward price-to-earnings ratio of about 15.7 suggest the balance sheet can sustain further R&D spending while funding share repurchases and dividends without overleveraging.

AbbVie has raised its dividend for over 50 consecutive years, delivering a current yield around 3.1% with a payout ratio below 50%. Historical data show total returns with dividends reinvested significantly outperform price appreciation alone—an effect likely to persist as management targets mid-single-digit annual dividend growth. For long-term investors, compounding through reinvestment and reliable cash distribution enhances total return potential even in volatile markets.